Stratification of neutropenia events by severity revealed higher incidence of grade 1 – 2 neutropenia among SYK and/or BTK inhibitors group in comparison to placebo group (RR 4.24; 95%CI: 1.00 – 18.01, p=0.05, I2 = 0%, random-effect model). The gene discussed is BTK; the disease is neutropenia.